Skip to product details

Chemical product profile

HONGKUN / PRODUCT DIRECTORY

Rifamycin S | CAS 13553-79-2

The quinone member of a structurally complex ansamycin family, rifamycin S links redox-sensitive identity with published rifamycin derivative chemistry; material review should separate related-rifamycin composition, chemical assay and any requested biological potency.

CAS13553-79-2
Molecular formulaC37H45NO12
Molecular weight695.8 g/mol

Product overview

Rifamycin S combines a quinone chromophore with an ansa bridge, multiple oxygen functions and defined stereochemical centres. The quinone state distinguishes S from its reduced hydroquinone relative, rifamycin SV. Rifamycin S is used in published semisynthetic work on brominated rifamycin intermediates and later derivatives, and is also employed in research. Selection should reflect the intended use: chemical conversion requires an S-specific assay and a resolved related-rifamycin profile, while biological studies may additionally require an activity assay suited to the experiment. Specify the S form, the analytical reference and the basis used to report content. Structural identification and chromatography together help establish the composition of this complex ansamycin.

Chemical identity

Chemical name
Rifamycin S
CAS number
13553-79-2
Molecular formula
C37H45NO12
Molecular weight
695.8 g/mol

Application context

Rifamycin derivative synthesis uses rifamycin S as a precursor to 3-bromorifamycin S, retaining the complex ansamycin framework while modifying the quinone-associated aromatic portion. For chemical conversion, the assay should distinguish S from SV and other relevant rifamycins. For biochemical research, define any activity requirement through a separate biological assay. Colour and optical rotation can complement identity review, while a selective chromatographic method establishes the component profile needed for the intended use.

Chemistry and synthetic role

The quinone/hydroquinone distinction separates rifamycin S from SV. The ansa bridge carries additional stereochemical and functional information, so a chromophore measurement alone does not prove the complete molecular identity.

Quality review

Resolve the redox form

Agree a method that distinguishes S from SV and any other relevant rifamycin components rather than reporting only total related chromophore.

Separate purity from potency

Chemical assay and antimicrobial activity are different measurements. Request a defined potency test only when the application actually requires one.

Review the complete ansamycin profile

Use identity evidence plus selective related-substances data; optical rotation can support, but cannot alone establish, stereochemical and compositional suitability.

Preparing a specification

Specify rifamycin S by CAS, intended conversion or research use, mass-assay basis and relevant rifamycin separation. If activity is needed, define the biological assay separately and confirm whether it is available.

Packaging and storage

Confirm packaging format, net weight and transport arrangements for the selected grade, order quantity and destination. Request the applicable SDS and label to establish storage and handling conditions.

Documentation

Request the proposed specification, batch COA and current SDS. Confirm availability of the analytical methods and batch evidence relevant to the intended process. Request chromatograms showing the redox-related separation and clarify whether any certificate reports chemical content, activity or both.

Procurement questions

Is rifamycin S the same as rifamycin SV?

No. They are distinct redox forms and should be identified and quantified accordingly.

Does HPLC purity guarantee potency?

No. Potency requires an appropriate biological assay if needed for the application.

Is colour sufficient to confirm the quinone material?

No. Use the agreed identity and selective composition tests; appearance is supplementary.

Technical sources
  1. PubChem CID 6436726: identity properties and CAS synonymsNCBI / PubChem
  2. Rifamycin S, R0200Tokyo Chemical Industry
  3. US9765088B2: Process for preparation of rifamycin derivativesUSPTO publication via Google Patents